<SEC-DOCUMENT>0001193125-18-182512.txt : 20180604
<SEC-HEADER>0001193125-18-182512.hdr.sgml : 20180604
<ACCEPTANCE-DATETIME>20180604073058
ACCESSION NUMBER:		0001193125-18-182512
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180603
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20180604
DATE AS OF CHANGE:		20180604

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			FIBROGEN INC
		CENTRAL INDEX KEY:			0000921299
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36740
		FILM NUMBER:		18876879

	BUSINESS ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-978-1200

	MAIL ADDRESS:	
		STREET 1:		409 ILLINOIS STREET
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d590719d8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML><HEAD>
<TITLE>8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">8-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT
REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Pursuant to Section&nbsp;13 or 15(d) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>of the Securities Exchange Act of 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): June&nbsp;3, 2018 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">001-36740</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">77-0357827</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>409 Illinois Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>San
Francisco, CA 94158 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive offices, including zip code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(415) <FONT STYLE="white-space:nowrap">978-1200</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Registrant&#146;s telephone number, including area code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Former
name or former address, if changed since last report.) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below
if the Form <FONT STYLE="white-space:nowrap">8-K</FONT> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule <FONT STYLE="white-space:nowrap">14a-12</FONT> under the Exchange Act (17 CFR <FONT STYLE="white-space:nowrap">240.14a-12)</FONT> </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;14d-2(b)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.14d-2(b))</FONT> </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">Pre-commencement</FONT> communications pursuant to <FONT STYLE="white-space:nowrap">Rule&nbsp;13e-4(c)</FONT> under the Exchange Act (17 CFR
<FONT STYLE="white-space:nowrap">240.13e-4(c))</FONT> </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Securities Exchange Act of 1934 <FONT STYLE="white-space:nowrap">(&#167;240.12b-2</FONT> of this chapter).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange
Act.&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;8.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Other Events </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On June&nbsp;3, 2018, FibroGen, Inc. issued a press release in which it
announced results from its clinical trial of pamrevlumab in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy in patients with locally advanced unresectable pancreatic
cancer. The results were presented in a discussion poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A copy of such press release is furnished as Exhibit&nbsp;99.1 to this report and is incorporated herein by reference. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD WIDTH="91%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00pt solid #000000; width:27.80pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;No.&nbsp;&nbsp;&nbsp;&nbsp;</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:39.50pt; display:inline; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d590719dex991.htm">Press Release titled &#147;FibroGen Presents Clinical Results of Pamrevlumab Treatment in Patients with Locally Advanced
 Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting&#148; dated June 3, 2018 </A></P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3"><B>FIBROGEN, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Dated: June&nbsp;4, 2018</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Lowenstein</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Michael Lowenstein</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Legal Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d590719dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g590719g42k78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">NEWS RELEASE </P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FibroGen Presents Clinical Results
of Pamrevlumab Treatment in Patients with Locally Advanced Unresectable Pancreatic Cancer at ASCO 2018 Annual Meeting </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Demonstrates
Enhanced Rate of Surgical Resection with Pamrevlumab in Patients with Previously Unresectable Disease </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SAN FRANCISCO, Calif., June&nbsp;3, 2018 &#150;
FibroGen, Inc. (NASDAQ: FGEN), a biopharmaceutical company, today announced Phase 1/2 clinical trial results of pamrevlumab in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT>
chemotherapy in patients with locally advanced unresectable pancreatic cancer (LAPC). Principal investigator Vincent J. Picozzi, Jr., M.D., Director, Pancreas Center of Excellence, Virginia Mason Cancer&nbsp;&amp; Digestive Diseases Institutes,
presented the results in a discussion poster session at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Pamrevlumab is a proprietary
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody targeting connective tissue growth factor (CTGF) under development for the treatment of fibrosis and fibroproliferative disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These are some of the most exciting clinical trial results in locally advanced pancreatic cancer I have seen since I began treating pancreatic cancer
patients,&#148; said Dr.&nbsp;Picozzi. &#147;The data suggest that pamrevlumab in combination with chemotherapy has the potential to become a neoadjuvant treatment regimen for locally advanced unresectable pancreatic cancer patients that has not
existed before.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patients with locally advanced pancreatic cancer (without metastasis) tend to have a poor prognosis with a median survival of
9&#150;18 months. In patients who have undergone resection of their tumor, median survival and five-year survival rates have been reported to be higher than those without resection. Therefore, treatment to achieve a surgical resection in this
patient population is a meaningful treatment goal to potentially achieve a favorable overall survival outcome. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In this open-label, randomized Phase 1/2
study, pamrevlumab was administered in combination with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> chemotherapy (gemcitabine and <FONT STYLE="white-space:nowrap">nab-paclitaxel)</FONT> and
compared to treatment with chemotherapy alone in patients with locally advanced pancreatic ductal adenocarcinoma, who were not eligible for surgical resection based on histology, computerized tomography (CT) scans, and laparoscopy criteria, prior to
randomization. Upon completion of the six months of study drug treatment, patients underwent surgical eligibility assessment based on <FONT STYLE="white-space:nowrap">pre-specified</FONT> objective criteria. The study enrolled 37 patients: 24
received pamrevlumab + chemotherapy: 13 received chemotherapy alone. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At ASCO 2018, FibroGen reported that a higher proportion of patients whose tumor was
previously considered unresectable became eligible for resection (based on protocol <FONT STYLE="white-space:nowrap">pre-specified</FONT> post-treatment surgical eligibility criteria) after receiving pamrevlumab and chemotherapy than after receiving
chemotherapy alone (at the end of 6 months of treatment), 70.8% vs. 15.4%. For those patients who met these surgical resection eligibility criteria at post-treatment assessment, individual patient condition and circumstance contributed to whether
resection subsequently occurred. A higher proportion of pamrevlumab-treated patients achieved surgical resection than those received chemotherapy alone, 33.3% vs. 7.7%. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the study, patients were followed for survival after evaluation for eligibility for resection and, when
applicable, after resection. Patients who had successful resections in this study had a statistically significant longer median survival benefit as compared to patients who did not undergo resection, 40 months vs.18.6 months (p=0.0141), as of May,
2018. FibroGen is continuing to monitor study patients for survival. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;Patients with unresectable locally advanced pancreatic cancer are in need of
an innovative and effective treatment with the potential to transform <FONT STYLE="white-space:nowrap">non-operable</FONT> cancer into resectable disease,&#148; said Elias Kouchakji, M.D., Senior Vice President, Clinical Development and Drug Safety.
&#147;The updated clinical results we are reporting at ASCO suggest that pamrevlumab may improve the treatment outcomes for patients who are currently deemed unresectable.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Locally Advanced Pancreatic Cancer </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In locally
advanced pancreatic cancer (LAPC), tumors typically encase structures, particularly blood vessels that are closely associated with the pancreas such as the superior mesenteric artery and superior mesenteric vein. Involvement of the cancer around
these blood vessels precludes surgical removal of the tumor. Approximately 80% of newly diagnosed LAPC patients are classified as having unresectable disease, and patients with unresectable LAPC have a median survival only slightly better than that
of patients with metastatic pancreatic cancer. Patients with resectable cancer whose tumors are surgically removed have a much better prognosis, with median survival of approximately 23 months, and some patients being cured. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Pamrevlumab</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B>Pamrevlumab is a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders
characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and has
been granted Orphan Drug Designation (ODD) in each of these indications, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD). Pamrevlumab recently received Fast Track designation from the U.S. Food and Drug Administration for
the treatment of patients with locally advanced unresectable pancreatic cancer. Pamrevlumab has demonstrated a good safety and tolerability profile in multiple Phase 2 trials conducted to date. For information about pamrevlumab studies currently
recruiting patients, please visit <U>www.clinicaltrials.gov</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About FibroGen </B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc., headquartered in San Francisco, with subsidiary offices in Beijing and Shanghai, is a leading biopharmaceutical company discovering and
developing a pipeline of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> therapeutics.&nbsp;The company applies its pioneering expertise in hypoxia-inducible factor (HIF), connective tissue growth
factor (CTGF) biology, and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the company&#146;s most advanced product candidate, is an oral small molecule inhibitor of HIF
prolyl hydroxylase activity in worldwide Phase 3 clinical development for the treatment of anemia in chronic kidney disease (CKD), with a New Drug Application currently under review in China by the State Drug Administration or SDA (formerly the
</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
China Food and Drug Administration). Roxadustat is in Phase 3 clinical development in the U.S. and Europe for anemia associated with myelodysplastic syndromes (MDS).&nbsp;Pamrevlumab, an
anti-CTGF human monoclonal antibody, is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD).
FibroGen is also developing a biosynthetic cornea in China. For more information, please visit <U>www.fibrogen.com</U>. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements
</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This release contains forward-looking statements regarding our strategy, future plans and prospects, including statements regarding the development
of the company&#146;s product candidates pamrevlumab and roxadustat, the potential safety and efficacy profile of our product candidates, and our clinical, regulatory, and commercial plans, and those of our partners. These forward-looking statements
include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as &#147;may,&#148; &#147;will&#148;, &#147;should,&#148;
&#147;on track,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;continue&#148; and similar words, although some
forward-looking statements are expressed differently. Our actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of our various
programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended
December&nbsp;31, 2017, and our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the fiscal quarter ended March&nbsp;31, 2018 filed with the Securities and Exchange Commission (SEC), including the risk factors set forth
therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and we undertake no obligation to update any forward-looking statement in this press release, except
as required by law.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"># # # </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Contact
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">FibroGen, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Karen L. Bergman </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Investor Relations and Corporate Communications </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 (415) <FONT STYLE="white-space:nowrap">978-1433</FONT> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>kbergman@fibrogen.com </U></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g590719g42k78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g590719g42k78.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M+VS=K:\URZ"M813HVTK9QY N#D$9'3.>U>I1PCO^\3C;8Y)UG'X3Y&;]HO\
M:DUJ0ZI9:QXF:W&6*Z7ICBQ5<Y*)F(@A1SU[5W/#X2G!N=2,;=WY_P#!.5UJ
M_P#([=['HG@#]NGXG>%=0CL?B%:#Q#IPD07 FMFL=5MH5R)'1-HWNHYQCG&*
MY)X:@]:34GY&L,3RM*3Y;=S]5_AO\1O"_P 3M L?$_A6^2[LK@*9(B52>SE"
M@R0W<(.4F4G'->=4ISIZ.+1Z$*T91^)61Z49(U!)8 +P?:N9M1W]TTBG+X5<
M;YT0(7>N> !GU. /KDBFMF^D5?Y+7\ :<>EAY=5'4 9Q^/2I4HO9WL(-RCN!
MC\.E-RBM+V#;Y!O08^8#) ';D]!3!/L =><,,+UYZ8J7*,>MK#LUTL-\V+CY
MUYZ<_P"<4.<8;M1L'*^VPHD0]&'''7'2FI1?PNZ06:Z6L?@G\6HUG_:XU>*2
M-)(S\3/#<3QN,HT4D^BI*K*?O!@P7'?(%?0X>O*GA4ET2_-^9X=7_>?Z_E/W
M 3P-X."C_BF=$P/NXTZV7"9^08,8Y";1^%>'/%5.;XI:6_)'L>SC+6VX'P3X
M-3_F6-% '?\ L^U'3K_RS[5'UNHOM25AJA'R5OZ[#SI&B:%97TNFZ+96D;VT
MSSQV=O%"MRB1-F.81J-RE<@9]:NE-UJBN[/1:[DSBJ<;+H?G5\%?BQ\&M4^.
MT>A>%_A#%H'B?4]7U:P_X2$7*20PS6#7"RW,,'_+)G2"3IC[U>I6I2A2O?1+
MMV3_ ,CFA\7:QF_\%'D_=?"DE2<S>)2L; KN,EM9 ;EZY1=H([;:K*X\\9K^
M^_R@<N,C^_IR_EIQ_"4F.^'?[6W@OX-? SP'X<MH)/$GBFWT^X%QIEIB*&TW
M7EQM6ZG;B%^APV#@@]ZG&9=>NY.W*VK?U8N.)Y(J*W7]=S,TG_@HIJ3:@?[9
M\ Q#3@^919WJ&ZAA!QN5LXE;'85T/*J;A"SL[?UI8J.+G&_1?UYGWU\(?C9X
M'^,6CMJOA34 UQ#&IO=,N2D>HV9&0!+"3N* Y&[&/SKR\1A)8?I==TK?A;0Z
M*>)Y]-O+^F<-^T3^T59_ :+PQ-<:!<Z[_P )#/=01+;3K"(A:Q1.S$-_K=PE
M)&.GD/2P%'ZVZR>U'D_\FYO7^4TKU?8J']Z_X6_S/FW7O^"A?AZUT;39M!\*
MWE_KDUN7O+2ZG-O:V!61E"M, 0[[@05.-N!ZUU3P"C?\/ZL8*NW_ %_P3Z@^
M 'QME^+O@"\\;:W8V?A]+.[G@F'GE[6&&W0R/)+(^%PJCKFN&MA^1Q2-:=3>
M^ECP+XG_ +>?A#POJ-UI7@S19_%DMHS0RZH]Q]ETP2(2I$!'^N0,!RO:MZ&!
M4[<VB_X;R,ZE?EVZ?UW///#'_!1(2WPB\6>!_L]BS()KG2;PS/%$S(N[[,PW
M/C=R5]!ZUZ#RFG[/1I.VGW=K&,,0Y2L]$O\ .W<_0SP!\1?"/Q+T"#Q!X4U*
M&_TY\*Z1LJW%G,,%K>YA#%DE4CD$ \&O"Q49X*=FK*^]M-VNMNQWPJ+E[6/D
M/]N3XQW?@OPI9^"=&N3::GXI60W]Q"^R2WTV,'S%5@<QF12!NXKT<LH<\EB;
M:132\KK^NIP8JMR1=M'='BO[(?[+>F>*;&W^)/Q!M/MMA(^-!TB[#F*8(23?
M7+-_K?[P/() KHQ6*]C[J>WX=NJ)P\75U/U,M= T6QMX[33M,T^WM8E58K>"
MRM4C2./ ) *9?@;0>>2*\66+O?F;DNKO]W6W0]&-&*TV_KT/GWXX_LT^#/BQ
MH=Z\6EV>D>*88I9]+UJR@2VE-RBAHHK\(JK+"Q7:<=-^>U=^$QE.%D[6?333
M?;_@G)6PL5JNG_ \C\_?V6=6^(/P9^+K>#]8T'7D\-ZQ>RZ/J$?V*]>Q@NHI
M66WOXY3'LCCD89SD @BN[%5:$\/4DK<T5>.VZ(H:5(4MN9V/V2FN(HH6GED2
M".&(N[2$(B*$WN7+8 **,G/05X$8NHUH>IS1I1WM;IZ'P5\5_P!NGP5X)U6Z
MT+P?I<_B[4+68Q7%Y'*MOH\,\#8D57!/G2*R\A">17K4,'>*C+W5)6M;T6]M
MK=+'!6Q3N[?9_P"#YGF/AS_@HI(=06/Q3X$6#3F=3Y^EW[3SQQ;AYDAMP"6*
MID[>^,5O++(0B^1\K6VW^2,88F3\OZ]3]#/AQ\3O"?Q1T"#Q#X3U.*\LWVB>
M#*FXLY",^5<1JQ:&0?W6 ->/B</*G)*VST?I\CLA431Y)^T'^T5:_ =/#K7?
MAZ[UH^(6ND012B#R&ML8+;A\HY'YUV83"^VOY/\ 3T%5G[$^=_$7_!0GPY;Z
M)IDOA_PC>7VNW<):_LKJ98+/39!]Y)93@7##T6NN>5J%^9Z=%:UMO(XGC&]N
MG]=S"\%_\%"[2ZU*&#QGX,.FZ;-.8Y=3TNX6X^SHI56:XMERT@4LH.W^\/6H
MKY7!Q]W6W_ \C58R2M?2W]=S]'?#_B32/%FBZ;X@\/WEKJ6DZG;)<V=W$ZE)
M(WZ$,C$'T^H([5X\Z3P[Y-OZ^7<ZX5>=7N?A3\==5;0/VFO&>O+$+AM#\;Z;
MJXMLX6X%A#I%T(BW\)+P(/\ @0]:^GPM&#PB<FHZ+=I=7W1Y%73$^G_R)]1I
M_P %(]2"J!\-K$A0 I&KR#*C[K80$#(P< ]ZX%EM.2YHOF3V:::[;\KVV.ZI
M7G3FX*+M&VR?9/HT-;_@I#J0*G_A6U@K[U*YUN4 KM<,"NWK\E/^RXKOIZ?_
M "!'UJHOLO3R?^9]\_##X@R?%+X3Z?XXETU=*?6M,O9C9),UPL>P2("LC $@
MXZ=JX945A\8J:T247_6B.B$W.ES/W;-[Z?F?D;^S)_R=3H?;'BSQ9[=!JM>]
MBU!85V:NH]U_*S&#7/NM^Y])?\%(N/\ A56#M)D\1DM]XA$BLB55?4YQFO.R
MB7)*71*;_P#;#/&?''R@OSD>2_LE_LO:?\4X)O'7C:*:3PI;SF#3=)BE,0U6
MXBVN_P!J8C(M59L$+W5AU%=.98M4Y1Y6KJVWJ_,QP]+FDN;1+O\ \%'WGXK_
M &1O@KXGT.XTJV\'6?AZZ$ 2QU?2/.@N;2X5?W<VR1OWBJP (.=W6N&&958\
MMVW'SNK?/F/3EA:*AHXZ><?T1^6NAW'BK]EKX])8R74FW2]6MH]2,;2+!K7A
MZ^N4C6:2(X26X$:L0$!P _I7I/EQ='W5S)KIKU\KVV/,@O9U;)[?Y'U5_P %
M$+J'4-#^%=] VZ"^?4+JV;[H>UGL(+F-@PX5@DF!Z[N*Y,L4:4L4H6<O<32W
M5N=+16M?='5CK6H=/C_]M_R,+]DC]E?PCX]\,CXB_$&UEU.TO[N=-$T7<T%M
M':02E7EN>C3AF ''3:?6C%XOV3Y=(RMU;7Z_Y$T:5[:;'2?MAZ_HGP;\&:1\
M(_AM9Q^&;;Q,\NH:K'IKR1$6:G;M$C-E-_0DGH:6!7UB=1S5E&*:;VWZ-W0\
M2U1C3LU[SM:Z[?(K?LH?LH>&/$/ARS^(7Q'TR345U%GFT30IQ*;9;2-E5+VZ
M; :9I#D!1U#$CI2Q.(6';C3:NNS]>B:UT%2INHDVG;T_X<^D?BC^R+\*O&?A
MZ\MM!\-VOA3Q"MK*-,U+1]UO ERB.8$N8I?O1LP7)X *CFN*EFE>-6E"2GR.
M<;R<6E:Z3VDEMY,JMAU""=)<T[JZCJTDFVVDKI*V_>R/SO\ V;_&_B#X(_'
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MDZ?"HYP$F\0EAUW*T-F-H'J,&N+*W:KR[)R^6\37%1_>0?:"_-GR%\&_C/\
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MXN<Z;BD]/7LT4?V-O@#KFO\ BB+XK^,;2ZATNPGFN=&-^KK<ZQJDOS2ZAY;
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M(O"_A_Q/8BP\1:/I^LV;[AY%_;1SA 0?NE@2I'8CI6D).G:W0QF?.=[^QS\
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?K#2([]XGNX[=Y]LK6JO'"QW.3E5D<?C1=KY!M\C_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
